IL124536A - Pharmaceutical compositions containing a glycine uptake antagonist - Google Patents

Pharmaceutical compositions containing a glycine uptake antagonist

Info

Publication number
IL124536A
IL124536A IL12453696A IL12453696A IL124536A IL 124536 A IL124536 A IL 124536A IL 12453696 A IL12453696 A IL 12453696A IL 12453696 A IL12453696 A IL 12453696A IL 124536 A IL124536 A IL 124536A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
glycine uptake
antagonist
uptake antagonist
Prior art date
Application number
IL12453696A
Other languages
English (en)
Other versions
IL124536A0 (en
Original Assignee
Daniel C Javitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21731199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daniel C Javitt filed Critical Daniel C Javitt
Publication of IL124536A0 publication Critical patent/IL124536A0/xx
Publication of IL124536A publication Critical patent/IL124536A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12453696A 1995-12-07 1996-12-05 Pharmaceutical compositions containing a glycine uptake antagonist IL124536A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US836195P 1995-12-07 1995-12-07
PCT/US1996/019142 WO1997020553A1 (en) 1995-12-07 1996-12-05 Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists

Publications (2)

Publication Number Publication Date
IL124536A0 IL124536A0 (en) 1998-12-06
IL124536A true IL124536A (en) 2001-03-19

Family

ID=21731199

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12453696A IL124536A (en) 1995-12-07 1996-12-05 Pharmaceutical compositions containing a glycine uptake antagonist

Country Status (10)

Country Link
US (3) US5837730A (xx)
EP (1) EP0871440B1 (xx)
JP (3) JP2000501707A (xx)
AT (1) ATE320804T1 (xx)
DE (1) DE69635959T2 (xx)
DK (1) DK0871440T3 (xx)
ES (1) ES2260773T3 (xx)
IL (1) IL124536A (xx)
PT (1) PT871440E (xx)
WO (2) WO1997020553A1 (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
WO1997020553A1 (en) * 1995-12-07 1997-06-12 Javitt Daniel C Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
PT1073432E (pt) 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
US6416975B1 (en) * 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
AU4361500A (en) * 1999-04-20 2000-11-02 Advocare International Llc Nutritional composition for improved cognitive performance
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
KR100900020B1 (ko) 2001-02-16 2009-06-01 알레릭스 뉴로사이언스, 인크. Ｇｌｙｔ-1 저해제로서의 티오펜 치환 아민 유도체
US20020187544A1 (en) * 2001-04-05 2002-12-12 Wisconsin Alumni Research Foundation Uropathogenic E. coli D-serine detoxification operon
WO2004005935A1 (ja) * 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
FR2843590B1 (fr) * 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
KR101095939B1 (ko) * 2003-01-16 2011-12-19 아카디아 파마슈티칼스 인코포레이티드 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2ａ／2ｃ 리셉터 역작용제
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
AU2004233942A1 (en) 2003-04-30 2004-11-11 H. Lundbeck A/S Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives
CN1867358A (zh) * 2003-08-21 2006-11-22 H.隆德贝克有限公司 用于治疗抑郁症的5－羟色胺再摄取抑制剂和1型甘氨酸转运蛋白抑制剂的联合药物
EP1696857A2 (en) * 2003-12-04 2006-09-06 The Research Foundation Of the City university of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
US20090017047A1 (en) * 2004-06-11 2009-01-15 Egon Tech Preparation for the Prevention and Treatment of Stress Conditions as Well as Functional and Organic Disorders of the Nervous System and Metabolic Disorders
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
CA2579962A1 (en) 2004-08-09 2006-06-01 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders
EP1830833B1 (en) * 2004-12-16 2010-01-27 Janssen Pharmaceutica N.V. Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
TW200820963A (en) * 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
CN101677971A (zh) 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
DK2200610T3 (en) * 2007-09-21 2018-04-23 Acadia Pharm Inc ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
US20110263968A1 (en) * 2008-11-04 2011-10-27 Mclean Hospital Corporation Drug-Enhanced Neurofeedback
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US8624052B2 (en) * 2010-11-12 2014-01-07 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN111491629A (zh) 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
AU2019206950B2 (en) * 2018-01-10 2021-07-01 XWPharma Ltd. Prodrugs of ketamine, compositions and uses thereof
WO2020150698A1 (en) * 2019-01-18 2020-07-23 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
CA3158912A1 (en) * 2019-11-18 2021-05-27 Societe Des Produits Nestle S.A. Compositions and methods for glutathione enhancement for use in brain health
AU2022326513A1 (en) 2021-08-13 2024-02-15 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
JPH07103018B2 (ja) * 1988-09-16 1995-11-08 武田薬品工業株式会社 精神分裂病治療剤
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5179085A (en) * 1989-03-15 1993-01-12 Warner-Lambert Company N-substituted α-amino acids and derivatives thereof having pharmaceutical activity
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5756348A (en) 1991-11-12 1998-05-26 Synaptic Pharmaceutical Corporation DNA encoding a glycine transporter and uses thereof
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
WO1997020553A1 (en) * 1995-12-07 1997-06-12 Javitt Daniel C Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists

Also Published As

Publication number Publication date
JP2009167205A (ja) 2009-07-30
DE69635959T2 (de) 2006-12-07
JP2013056918A (ja) 2013-03-28
US5837730A (en) 1998-11-17
EP0871440B1 (en) 2006-03-22
EP0871440A1 (en) 1998-10-21
EP0871440A4 (en) 1999-01-20
JP5363152B2 (ja) 2013-12-11
DE69635959D1 (de) 2006-05-11
ATE320804T1 (de) 2006-04-15
WO1997020553A1 (en) 1997-06-12
ES2260773T3 (es) 2006-11-01
WO1997020552A1 (en) 1997-06-12
JP2000501707A (ja) 2000-02-15
IL124536A0 (en) 1998-12-06
US5854286A (en) 1998-12-29
US6162827A (en) 2000-12-19
PT871440E (pt) 2006-07-31
DK0871440T3 (da) 2006-07-10

Similar Documents

Publication Publication Date Title
IL124536A (en) Pharmaceutical compositions containing a glycine uptake antagonist
CA1264740C (en) TETRAPYRROLE THERAPEUTIC AGENTS
MX9802564A (es) Composiciones de dipeptidos angioestaticas farmaceuticas y metodos para usar las mismas.
AU5689086A (en) New tetrapyrrole therapeutic agents
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
IL113625A0 (en) Amino acid derivatives processes for their preparation and pharmaceutical compositions containing them and their use
GR1003164B (el) Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης.
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
EP0715857A3 (de) Pharmazeutische, oral anwendbare Zubereitungen enthaltend als Zerfallbeschleuniger eine wasserlösliche Aminosäure
GR3026369T3 (en) Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist.
PL343069A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
MY124560A (en) Amino acid compositions and use thereof in immunosuppression
ES2099021A1 (es) Composicion farmaceutica que tiene actividad analgesica.
DE69213935D1 (en) Neue heterocyclische carbonsäuren
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
NZ337798A (en) Pharmaceutical compositions containing lamivudine
MX9708557A (es) Nuevo uso farmacologico de los antagonistas del receptor aii.
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
YU40398A (sh) Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees